Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.

Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O.

Clin Cancer Res. 2011 Jun 1;17(11):3841-9. doi: 10.1158/1078-0432.CCR-10-2806. Epub 2011 Apr 29.

2.

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.

Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S, Akaza H; Japan Axitinib Phase II Study Group.

Eur J Cancer. 2011 Nov;47(17):2592-602. doi: 10.1016/j.ejca.2011.07.014. Epub 2011 Aug 31.

PMID:
21889330
3.

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.

Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O.

Clin Cancer Res. 2011 Dec 1;17(23):7462-9. doi: 10.1158/1078-0432.CCR-11-0534. Epub 2011 Oct 5.

4.

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J.

J Clin Oncol. 2009 Aug 10;27(23):3836-41. doi: 10.1200/JCO.2008.20.8355. Epub 2009 Jul 13.

PMID:
19597027
5.

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP.

J Clin Oncol. 2009 Sep 20;27(27):4462-8. doi: 10.1200/JCO.2008.21.7034. Epub 2009 Aug 3.

PMID:
19652060
8.

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.

Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, Minami H.

Cancer Sci. 2010 Apr;101(4):963-8. doi: 10.1111/j.1349-7006.2009.01465.x. Epub 2009 Dec 9.

9.

Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison.

Lee HY, Kang HJ, Koo BK, Oh BH, Heung-Sun K, Kim KS, Seo HS, Ro YM, Kang JH, Woong CJ, Joo SJ, Kim MH, Joon-Han S, Yoon J, Park SH, Jin-Ok J, Ju AK, Chong-Yun R, Yeon KJ, Park KM, Lim DK, Park SY; Amostar Study Investigators.

Clin Ther. 2005 Jun;27(6):728-39.

PMID:
16117979
10.

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.

Rini BI, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, Bair AH, Grünwald V.

Ann Oncol. 2015 Jul;26(7):1372-7. doi: 10.1093/annonc/mdv103. Epub 2015 Feb 20.

PMID:
25701454
11.

Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.

Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I.

Clin Ther. 2007 Feb;29(2):279-89.

PMID:
17472820
12.

An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.

Miranda RD, Mion D Jr, Rocha JC, Kohlmann O Jr, Gomes MA, Saraiva JF, Amodeo C, Filho BL.

Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008.

PMID:
18840367
13.

The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.

Rössler J, Monnet Y, Farace F, Opolon P, Daudigeos-Dubus E, Bourredjem A, Vassal G, Geoerger B.

Int J Cancer. 2011 Jun 1;128(11):2748-58. doi: 10.1002/ijc.25611. Epub 2010 Oct 8.

14.

Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.

Pomara G, Morelli G, Pomara S, Taddei S, Ghiadoni L, Dinelli N, Travaglini F, Dicuio M, Mondaini N, Salvetti A, Selli C.

J Androl. 2004 Jul-Aug;25(4):625-9.

15.
17.

Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency.

Ahmad AM, Hopkins MT, Weston PJ, Fraser WD, Vora JP.

Clin Endocrinol (Oxf). 2002 Apr;56(4):431-7.

PMID:
11966735
18.

Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.

Chen Y, Rini BI, Bair AH, Mugundu GM, Pithavala YK.

Clin Pharmacokinet. 2015 Apr;54(4):397-407. doi: 10.1007/s40262-014-0207-5.

PMID:
25343945
19.

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.

Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE.

Cancer. 2014 Sep 1;120(17):2694-703. doi: 10.1002/cncr.28766. Epub 2014 May 20.

20.

A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension.

Conlin PR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM.

J Hum Hypertens. 1998 Oct;12(10):693-9.

PMID:
9819017

Supplemental Content

Support Center